MedTrace Logo

Reirradiation With Concurrent Paclitaxel for Breast Cancer

NCT02058667 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2016-11-15

No results posted yet for this study

Summary

The purpose of this trial in addition to a dose finding study for concurrent Paclitaxel, will be to establish a treatment algorithm for chest wall reirradiation. A nominal margin of at least 5cm will be used on the protocol and extending it to 7cm. Considering the standard treatment of breast cancer incorporates a cumulative dose of 60Gy, delivering an additional 50.4 Gy followed by a boost should target a total dose of 120 Gy.

Conditions

Interventions

RADIATION

Paclitaxel+Initial Radiation+Boost

Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)

Sponsors & Collaborators

  • University of Kentucky

    lead OTHER

Principal Investigators

  • Jonathan M Feddock, MD · UK Markey Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02058667 on ClinicalTrials.gov